Cargando…

Prospects for immunotherapy and vaccines against Cryptosporidium

Cryptosporidium spp is a ubiquitous parasite that has long been recognized as a frequent cause of protozoal diarrhea in humans. While infections in immunocompetent hosts are usually self-limiting, immunocompromised individuals can develop severe, chronic, and life-threatening illness. Vaccine develo...

Descripción completa

Detalles Bibliográficos
Autor principal: Mead, Jan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185963/
https://www.ncbi.nlm.nih.gov/pubmed/24638018
http://dx.doi.org/10.4161/hv.28485
_version_ 1782337984586055680
author Mead, Jan R
author_facet Mead, Jan R
author_sort Mead, Jan R
collection PubMed
description Cryptosporidium spp is a ubiquitous parasite that has long been recognized as a frequent cause of protozoal diarrhea in humans. While infections in immunocompetent hosts are usually self-limiting, immunocompromised individuals can develop severe, chronic, and life-threatening illness. Vaccine development or immunotherapy that prevents disease or reduces the severity of infection is a relevant option since efficacious drug treatments are lacking. In particular, children in developing countries might benefit the most from a vaccine since cryptosporidiosis in early childhood has been reported to be associated with subsequent impairment in growth, physical fitness, and intellectual capacity. In this review, immunotherapies that have been used clinically are described as well as experimental vaccines and their evaluation in vivo.
format Online
Article
Text
id pubmed-4185963
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41859632016-02-03 Prospects for immunotherapy and vaccines against Cryptosporidium Mead, Jan R Hum Vaccin Immunother Review Cryptosporidium spp is a ubiquitous parasite that has long been recognized as a frequent cause of protozoal diarrhea in humans. While infections in immunocompetent hosts are usually self-limiting, immunocompromised individuals can develop severe, chronic, and life-threatening illness. Vaccine development or immunotherapy that prevents disease or reduces the severity of infection is a relevant option since efficacious drug treatments are lacking. In particular, children in developing countries might benefit the most from a vaccine since cryptosporidiosis in early childhood has been reported to be associated with subsequent impairment in growth, physical fitness, and intellectual capacity. In this review, immunotherapies that have been used clinically are described as well as experimental vaccines and their evaluation in vivo. Landes Bioscience 2014-06-01 2014-03-17 /pmc/articles/PMC4185963/ /pubmed/24638018 http://dx.doi.org/10.4161/hv.28485 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Review
Mead, Jan R
Prospects for immunotherapy and vaccines against Cryptosporidium
title Prospects for immunotherapy and vaccines against Cryptosporidium
title_full Prospects for immunotherapy and vaccines against Cryptosporidium
title_fullStr Prospects for immunotherapy and vaccines against Cryptosporidium
title_full_unstemmed Prospects for immunotherapy and vaccines against Cryptosporidium
title_short Prospects for immunotherapy and vaccines against Cryptosporidium
title_sort prospects for immunotherapy and vaccines against cryptosporidium
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185963/
https://www.ncbi.nlm.nih.gov/pubmed/24638018
http://dx.doi.org/10.4161/hv.28485
work_keys_str_mv AT meadjanr prospectsforimmunotherapyandvaccinesagainstcryptosporidium